众生药业：控股子公司RAY1225注射液新增适应症临床试验获批

Core Viewpoint - The company has received approval from the National Medical Products Administration for the Phase III clinical trial of its innovative peptide drug RAY1225 injection, which now includes a new indication for the treatment of "obesity combined with obstructive sleep apnea" [1] Group 1 - The company's subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., is responsible for the development of RAY1225 injection [1] - The approval includes a notification for the clinical trial of the new indication [1] - This development highlights the company's commitment to expanding its product pipeline in the biopharmaceutical sector [1]